# Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

> **NCT04783675** · PHASE2 · COMPLETED · sponsor: **Children's Hospital of Fudan University** · enrollment: 44 (actual)

## Conditions studied

- Steroid-Sensitive Nephrotic Syndrome

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04783675
- **Lead sponsor:** Children's Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-13
- **Primary completion:** 2023-01-17
- **Final completion:** 2023-01-17
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-07-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04783675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04783675, "Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04783675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*